Adynovate, is a recombinant pegylated anti-hemophilic factor used for treatment of hemophilia A in patients who experience repeated bleeding events. Adynovate works by increasing levels of blood-clotting factor VIII in the blood in a temporary manner. Adynovate has an extended circulation time in the human body leading to reduced frequency of injection. The structure comprises coagulation factor VIII conjugated to PEG. Some common side effects include diarrhea, nausea, headache, vomiting, rash and other common allergic reactions.